Diabetes. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Ala12Ala or Pro12Ala genotype who will received DHA supplement: DHA supplement in shape of soft gel, 2 gram per day for 12 weeks, twice a day with main meal. Intervention 2: Ala12Ala o
Treatment - Other
Placebo
Pro12Pro genotype who will received DHA supplement: DHA supplement in shape of soft gel, 2 gram per day for 12 weeks, twice a day with main meal
Pro12Pro genotype who will received placebo: sunflower oil as placebo in shape of soft gel, 2 gram per day for 12 weeks, twice a day with main meal
Ala12Ala or Pro12Ala genotype who will received DHA supplement: DHA supplement in shape of soft gel, 2 gram per day for 12 weeks, twice a day with main meal
Ala12Ala or Pro12Ala genotype who will received placebo : sunflower oil as placebo in shape of soft gel, 2 gram per day for 12 weeks, twice a day with main meal
Sponsors
Tehran University of Medical Sciences
Endocrinology and Metabolism Research Institute
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Type 2 diabetic willing to participate in the study;BMI (kg/m2) between 18.5 to 35; Age from 30 to 60 year Exclusion criteria: Insulin therapy; Thiazolidinediones therapy; Liver, kidney, coagulation and thyroid disorders; Anticoagulation, ant-inflammation and lipid lowering drug consumption; History of Allergic reaction to fish or fish oil; Daily consumption of fish or w3 supplement; Supplementation with vitamin A,D and B6
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TG. Timepoint: before and after of intervention. Method of measurement: Enzymatic kit.;HDL.c. Timepoint: before and after of intervention. Method of measurement: Enymatic kit.;LDL.c. Timepoint: before and after of itervention. Method of measurement: Enzymatic Kit.;Chol. Timepoint: before and after of intervention. Method of measurement: Enzymatic kit.;ABCA1 gene expression. Timepoint: before and after of intervention. Method of measurement: Real time PCR.;LXRa gene expression. Timepoint: before and after of intervention. Method of measurement: Real time PCR. | — |
Secondary
| Measure | Time frame |
|---|---|
| Waist circumference. Timepoint: before and after of interention. Method of measurement: tape meter.;Weight. Timepoint: before and after of intervention. Method of measurement: digital scale.;BMI. Timepoint: before and after of intervention. Method of measurement: It is calculated by dividing weight(Kg) by height squar(m).;Body fat percent. Timepoint: before and after of intervention. Method of measurement: BIA.;Fasting blood sugar. Timepoint: before and after of sintervention. Method of measurement: Enzymatic Kit.;Insulin. Timepoint: before and after of study. Method of measurement: Radioimmunoassy kit(RIA).;Adiponectine. Timepoint: before and after of intervention. Method of measurement: ELISA kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAnahita Mansoori
Tehran University of Medical Sciences
Outcome results
None listed